BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
Bergen, Norway – 7 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2021 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2021 and ESEF file are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/reports/ Contacts: For BerGenBio: Martin Olin CEO, BerGenBio ASA